表紙
市場調查報告書

病毒載體、非病毒載體、基因治療藥製造的全球市場:2019年∼2030年

Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)

出版商 ROOTS ANALYSIS 商品編碼 914381
出版日期 內容資訊 英文 423 Pages
商品交期: 最快1-2個工作天內
價格
病毒載體、非病毒載體、基因治療藥製造的全球市場:2019年∼2030年 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)
出版日期: 2019年10月31日內容資訊: 英文 423 Pages
簡介

本報告提供全球病毒載體、非病毒載體、基因治療藥製造市場相關調查分析,市場現狀,年度需求,整體市場形勢,生產能力,產業企業,最近的聯盟、夥伴關係契約,原價分析,市場的推動要素與課題等相關的系統性資訊。

第1章 序文

第2章 摘要整理

第3章 簡介

第4章 病毒載體、基因治療藥廠商 (產業企業) :競爭情形

  • 概要
  • 整體市場形勢

第5章 質體DNA、基因治療藥廠商 (產業企業) :競爭情形

  • 概要
  • 整體市場形勢

第6章 媒介、基因治療藥廠商 (非前世的業緣界企業) :競爭情形

  • 概要
  • 整體市場形勢

第7章 北美的媒介、基因治療藥廠商

  • 概要
  • Aldevron
  • BioReliance / SAFC Commercial (Merck KGaA)
  • bluebird bio
  • Brammer Bio
  • FUJIFILM Diosynth Biotechnologies
  • MassBiologics
  • Novasep
  • Spark Therapeutics
  • Vigene Biosciences

第8章 歐洲的媒介、基因治療藥廠商

  • 概要
  • Biovian
  • Cell and Gene Therapy Catapult
  • Cobra Biologics
  • FinVector
  • Kaneka Eurogentec
  • Lonza
  • MolMed
  • Oxford BioMedica
  • Richter-Helm
  • Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
  • uniQure
  • VIVEbiotech

第9章 亞太地區的媒介、基因治療藥廠商

  • 概要
  • Wuxi AppTec
  • 其他

第10章 新興媒介

  • 概要

第11章 最近的聯盟、夥伴關係

第12章 主要考察

第13章 病毒載體、質體DNA原價分析

第14章 生產能力分析

第15章 需求分析

第16章 市場規模、機會分析

第17章 主要促進因素、課題

第18章 調查分析

第19章 結論

第20章 執行考察

第21章 附錄1:圖表資料

第22章 附錄2:企業、組織的清單

目錄

Example Insights:

Close to 100 industry players and over 80 non-industry players, based in different regions across the globe, claim to manufacture different types of viral and non-viral vectors in-house or on contract basis.

Overview:

Over the last 12 months, the pharmaceutical industry reported a year-on-year increment of nearly 75% in funding to support the development of various cell and gene therapies. In fact, close to USD 5 billion has been invested into research on gene-based therapies in the previous two decades. Interestingly, over 2,600 clinical studies have been initiated in this field of research, since 1989. The aforementioned numbers are indicative of the rapid pace of development in this upcoming segment of the biopharmaceutical industry. The development of such therapy products require gene delivery vehicles, called vectors, to desired locations within the body (in vivo) / specific cells (ex vivo). The growing demand for such therapies and the rising number of clinical research initiatives in this domain has led to an increase in demand for preclinical and clinical grade gene delivery vectors. Fundamentally, genetic modifications can be carried out using either viral (such as adenovirus, adeno associated virus (AAV), lentivirus, retrovirus, Sendai virus, herpes simplex virus, vaccinia virus, baculovirus and alphavirus) or non-viral (such as plasmid DNA) vectors. Moreover, recent advances in vector research have led to the development of several innovative viral / non-viral gene delivery approaches.

At present, 10+ genetically modified therapies have received approval / conditional approval in various regions of the world; these include (in the reverse chronological order of year of approval) Zynteglo™ (2019), Zolgensma® (2019), Collategene® (2019), LUXTURNA™ (2017), YESCARTA™ (2017), Kymriah™ (2017), INVOSSA™ (2017), Zalmoxis® (2016), Strimvelis™ (2016), Imlygic® (2015), Neovasculagen® (2011), Rexin-G® (2007), Oncorine® (2005) and Gendicine® (2003). In addition, over 500 therapy candidates are being investigated across different stages of development. The growing number of gene-based therapies, coupled to their rapid progression through the drug development process, has created significant opportunities for companies with expertise in vector manufacturing. Presently, a number of industry (including both well-established companies and smaller R&D-focused initiatives), and non-industry players (academic institutes) claim to be capable of manufacturing different types of viral and non-viral vectors. In addition, there are several players offering novel technology solutions, which are capable of improving existing genetically modified therapy products and upgrading their affiliated manufacturing processes. Considering prevalent and anticipated future trends, we believe that the vector and gene therapy manufacturing market is poised to grow steadily, driven by a robust pipeline of therapy candidates and technical advances aimed at mitigating existing challenges related to gene delivery vector and advanced therapy medicinal products.

Scope of the Report:

The “Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)” report features an extensive study of the rapidly growing market of viral and non-viral vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies with in-house manufacturing facilities. The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different regions of the globe. Amongst other elements, the report includes:

  • An overview of the current status of the market with respect to the players involved (both industry and non-indutry) in manufacturing viral vectors, non-viral vectors and other novel types of vectors. It features information on the year of establishment, scale of production, type of vectors manufactured, location of manufacturing facilities, applications of vectors (in gene therapy, cell therapy, vaccines and others), and purpose of production (fulfilling in-house requirements / for contract services).
  • An informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength.
  • An estimate of the overall, installed vector manufacturing capacity of industry players based on information available in the public domain, and insights generated via both secondary and primary research. The analysis also highlights the distribution of the global capacity by vector type (viral vector and plasmid DNA), scale of operation (clinical and commercial), size of the company / organization (small-sized, mid-sized and large) and key geographical regions (North America, Europe, Asia Pacific and the rest of the world).
  • An in-depth analysis of viral vector and plasmid DNA manufacturers, featuring three schematic representations; namely [A] a three dimensional grid analysis, representing the distribution of vector manufacturers (on the basis of type of vector) across various scales of operation and purpose of production (in-house operations and contract manufacturing services), [B] a logo landscape of viral vector and plasmid DNA manufacturers based on the type (industry and non-industry) and the size of the industry player (small-sized, mid-sized and large companies), and [C] a schematic world map representation, highlighting the geographical locations of vector manufacturing hubs.
  • An analysis of recent collaborations and partnership agreements inked in this domain since 2015; it includes details of deals that were / are focused on the manufacturing of vectors, whihc were analyzed on the basis of year of agreement, type of agreement, type of vector involved, and scale of operation (laboratory, clinical and commercial).
  • An analysis of the various factors that are likely to influence the pricing of vectors, featuring different models / approaches that may be adopted by product developers / manufacturers in order to decide the prices of proprietary vectors.
  • An overview of other viral / non-viral gene delivery approaches that are currently being researched for the development of therapies involving genetic modification.
  • Elaborate profiles of key players based in North America, Europe and Asia-Pacific (shortlisted based on scale of operation). Each profile features an overview of the company / organization, its financial performance (if available), information on its manufacturing facilities, vector manufacturing technology and an informed future outlook.
  • A discussion on the factors driving the market and the various challenges associated with the vector production process.

One of the key objectives of this report was to evaluate the current market size and the future opportunity associated with the vector manufacturing market, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies, anticipated growth in target patient population, existing price variations across different vector types, and the anticipated success of gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] type of vectors (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [B] applications (gene therapy, cell therapy and vaccines), [C] therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others), [D] scale of operation (preclinical, clinical and commercial) and [E] geography (North America, Europe, Asia Pacific and rest of the world).

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. For the purpose of the study, we invited over 160 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. Our opinions and insights presented in this study were influenced by discussions held with several key players in this domain. The report features detailed transcripts of interviews held with the stakeholders:

  • Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences)
  • Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals)
  • Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
  • Olivier Boisteau, (Co-Founder / President, Clean Cells), Laurent Ciavatti (Business Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells)
  • Joost van den Berg (Director, Amsterdam BioTherapeutics Unit)
  • Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital)
  • Colin Lee Novick (Managing Director, CJ Partners)
  • Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)
  • Semyon Rubinchik (Scientific Director, ACGT)
  • Alain Lamproye (President of Biopharma Business Unit, Novasep)
  • Astrid Brammer (Senior Manager Business Development, Richter-Helm)
  • Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing)
  • Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Marketing Manager, Plasmid Factory)
  • Nicolas Grandchamp (R&D Leader, GEG Tech)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the vector and gene therapy manufacturing market in the short to mid-term, and long term.

Chapter 3 is a general introduction to the various types of viral and non-viral vectors. It includes a detailed discussion on the design, manufacturing requirements, advantages, limitations and applications of currently available gene delivery vehicles. The chapter also provides a brief description of the clinical and approved pipeline of genetically modified therapies. Further, it includes a review of the latest trends and innovations in the contemporary vector manufacturing market.

Chapter 4 provides a detailed overview of around 80 companies, featuring both contract service providers and in-house manufacturers that are actively involved in the production of viral vectors and / or gene therapies utilizing viral vectors. The chapter provides details on the year of establishment, scale of production, type of viral vectors manufactured (AAV, adenoviral, lentiviral, retroviral and others), location of manufacturing facilities, applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of production (fulfilling in-house requirements / for contract services).

Chapter 5 provides an overview of around 30 industry players that are actively involved in the production of plasmid DNA and other non-viral vectors and / or gene therapies utilizing non-viral vectors. The chapter provides details on the year of establishment, scale of production, location of manufacturing facilities, applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of vector production (fulfilling in-house requirements / for contract services).

Chapter 6 provides an overview of around 80 non-industry players (academia and research institutes) that are actively involved in the production of vectors (both viral and non-viral) and / or gene therapies. The chapter provides details on the year of establishment, scale of production, location of manufacturing facilities, type of vectors manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others), applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of vector production (fulfilling in-house requirements / for contract services).

Chapter 7 features detailed profiles of the US based contract service providers / in-house manufacturers that possess commercial scale capacities for the production of viral vectors / plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.

Chapter 8 features detailed profiles of EU based contract service providers / in-house manufacturers that possess commercial scale capacities for the production of viral vectors / plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience, and an informed future outlook.

Chapter 9 features detailed profiles of Asia-Pacific based contract service provider(s) / in-house manufacturer(s) that possess commercial scale capacities for production of viral vectors / plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience, and an informed future outlook.

Chapter 10 provides detailed information on other viral / non-viral vectors (including alphavirus vectors, Bifidobacterium longum vectors, Listeria monocytogenes vectors, myxoma virus based vectors, Sendai virus based vectors, self-complementary vectors (improved versions of AAV), and minicircle DNA and Sleeping Beauty transposon vectors (non-viral gene delivery approach)) that are currently being utilized by pharmaceutical players to develop gene therapies, T-cell therapies and certain vaccines, as well. This chapter presents overview on all the aforementioned types of vectors, along with examples of companies that use them in their proprietary products. It also includes examples of companies that are utilizing specific technology platforms for the development / manufacturing of some of these novel vectors.

Chapter 11 features an elaborate analysis and discussion of the various collaborations and partnerships related to the manufacturing of vectors or gene therapies, which have been inked amongst players. It includes a brief description of the purpose of the partnership models (including licensing agreements, mergers / acquisitions, product development, service alliances, manufacturing, and others) that have been adopted by the stakeholders in this domain, since 2015. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 12 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of viral vectors and plasmid DNA manufacturers on the basis of their scale of production and purpose of manufacturing (fulfilling in-house requirement / contract service provider). In addition, it consists of a logo landscape, representing the distribution of viral vector and plasmid DNA manufacturers based on the type of organization (industry / non-industry) and size of employee base. The chapter also consists of six world map representations of manufacturers of viral / non-viral vectors (lentiviral, adenoviral, AAV and retroviral vectors, and plasmid DNA), depicting the most active geographies in terms of the presence of the organizations. Furthermore, we have provided a schematic world map representation to highlight the locations of global vector manufacturing hubs across different continents.

Chapter 13 highlights our views on the various factors that may be taken into consideration while pricing viral vectors / plasmid DNA. It features discussions on different pricing models / approaches that manufacturers may choose to adopt to decide the prices of their proprietary products.

Chapter 14 features an informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies. This section offers an opinion on the required scale of supply (in terms of vector manufacturing services) in this market. For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vector-based therapies that have been registered till date. The data was analysed on the basis of various parameters, such as number of annual clinical doses, trial location, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the marketed vector-based therapies, based on various parameters, such as target patient population, dosing frequency and dose strength.

Chapter 15 features an informed analysis of the overall installed capacity of the vectors and gene therapy manufacturers. The analysis is based on meticulously collected data (via both secondary and primary research) on reported capacities of various small-sized, mid-sized and large companies, distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the vector production capabilities of the organizations across different types of vectors (viral vectors, plasmid DNA, and both), scale of operation (clinical and commercial) and geographies (North America, EU, Asia-Pacific and the rest of the world).

Chapter 16 presents a comprehensive market forecast analysis, highlighting the likely growth of vector and gene therapy manufacturing market till the year 2030. We have segmented the financial opportunity on the basis of [A] type of vectors (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [B] applications (gene therapy, cell therapy and vaccines), [C] therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others), [D] scale of operation (preclinical, clinical and commercial) and [E] geography (North America, Europe, Asia Pacific and rest of the world). Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.

Chapter 17 provides details on the various factors associated with popular viral vectors and plasmid DNA that act as market drivers and the various challenges associated with the production process. This information has been validated by soliciting the opinions of several industry stakeholders active in this domain.

Chapter 18 presents insights from the survey conducted on over 160 stakeholders involved in the development of different types of gene therapy vectors. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 19 summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 20 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the vector and gene therapy manufacturing domain. In this study, we spoke to Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences), Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences), Olivier Boisteau, (Co-Founder / President, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells), Laurent Ciavatti (Business Development Manager, Clean Cells), Joost van den Berg (Director, Amsterdam BioTherapeutics Unit), Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital), Colin Lee Novick (Managing Director, CJ Partners), Cedric Szpirer (Executive & Scientific Director, Delphi Genetics), Semyon Rubinchik (Scientific Director, ACGT), Alain Lamproye (President of Biopharma Business Unit, Novasep), Astrid Brammer (Senior Manager Business Development, Richter-Helm), Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing), Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Marketing Manager, Plasmid Factory), and Nicolas Grandchamp (R&D Leader, GEG Tech).

Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 22 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Viral and Non-Viral Methods of Gene Transfer
  • 3.3. Viral Vectors for Genetically Modified Therapies
  • 3.4. Types of Viral Vectors
    • 3.4.1. Adeno-associated Viral Vectors
    • 3.4.2. Adenoviral Vectors
    • 3.4.3. Lentiviral Vectors
    • 3.4.4. Retroviral Vectors
    • 3.4.5. Other Viral Vectors
      • 3.4.5.1. Alphavirus
      • 3.4.5.2. Foamy Virus
      • 3.4.5.3. Herpes Simplex Virus
      • 3.4.5.4. Sendai Virus
      • 3.4.5.5. Simian Virus
      • 3.4.5.6. Vaccinia Virus
  • 3.5. Types of Non-Viral Vectors
    • 3.5.1. Plasmid DNA
    • 3.5.2. Liposomes, Lipoplexes and Polyplexes
    • 3.5.3. Oligonucleotides
    • 3.5.4. Other Non-Viral Vectors
    • 3.5.5. Gene Delivery using Non-Viral Vectors
      • 3.5.5.1. Biolistic Methods
      • 3.5.5.2. Electroporation
      • 3.5.5.3. Receptor Mediated Gene Delivery
      • 3.5.5.4. Gene Activated Matrix (GAM)
  • 3.6. Applications of Viral and Non-Viral Vectors
    • 3.6.1. Type of Therapy
      • 3.6.1.1. Gene Therapy
      • 3.6.1.2. Vaccinology
  • 3.7. Current Trends in Vector Development / Manufacturing
    • 3.7.1. Vector Engineering
    • 3.7.2. Cargo Engineering
  • 3.8. Vector Manufacturing
    • 3.8.1. Types of Vector Manufacturers
    • 3.8.2. Viral Vector Manufacturing Processes
      • 3.8.2.1 Vector Production
      • 3.8.2.2. Adherent and Suspension Cultures
      • 3.8.2.3. Unit Process Versus Multiple Parallel Processes
      • 3.8.2.4. Cell Culture Systems for Production of Viral Vectors
        • 3.8.2.4.1. Small / Laboratory Scale Cell Culture Systems
        • 3.8.2.4.2. Large Scale Cell Culture Systems
          • 3.8.2.4.2.1. Stirred-Tank Reactor Systems
          • 3.8.2.4.2.2. Fixed Bed Reactor / Packed Bed Reactor
          • 3.8.2.4.2.3. WAVE Bioreactor System
      • 3.8.2.5. Serum-Containing versus Serum-Free Media
    • 3.8.3. Bioprocessing of Viral Vectors
      • 3.8.3.1. AAV Vector Production
      • 3.8.3.2. Adenoviral Vector Production
      • 3.8.3.3. Lentiviral Vector Production
      • 3.8.3.4. γ -Retroviral Vector Production
    • 3.8.4. Challenges Related to Vector Manufacturing
  • 3.9. Future of Vector Manufacturing

4. VIRAL VECTOR AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): COMPETITIVE LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Viral Vector and Gene Therapy Manufacturers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Geographical Location of Headquarters
    • 4.2.4. Analysis by Geographical Location of Manufacturing Facilities
    • 4.2.5. Analysis by Type of Manufacturer
    • 4.2.6. Analysis by Purpose of Production
    • 4.2.7. Analysis by Type of Vector
    • 4.2.8. Analysis by Scale of Production
    • 4.2.9. Analysis by Application Area

5. PLASMID DNA AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): COMPETITIVE LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Plasmid DNA and Gene Therapy Manufacturers: Overall Market Landscape
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size
    • 5.2.3. Analysis by Geographical Location of Headquarters
    • 5.2.4. Analysis by Geographical Location of Manufacturing Facilities
    • 5.2.5. Analysis by Type of Manufacturer
    • 5.2.6. Analysis by Purpose of Production
    • 5.2.7. Analysis by Scale of Production
    • 5.2.8. Analysis by Application Area

6. VECTOR AND GENE THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): COMPETITIVE LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Vector and Gene Therapy Manufacturers: Overall Market Landscape
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Geographical Location of Manufacturing Facilities
    • 6.2.3. Analysis by Purpose of Production
    • 6.2.4. Analysis by Scale of Production
    • 6.2.5. Distribution by Application Area

7. VECTOR AND GENE THERAPY MANUFACTURERS IN NORTH AMERICA

  • 7.1. Chapter Overview
  • 7.2. Aldevron
    • 7.2.1. Company Overview
    • 7.2.2. Manufacturing Facilities
    • 7.2.3. Manufacturing Experience
    • 7.2.4. Future Outlook
  • 7.3. BioReliance / SAFC Commercial (Merck KGaA)
    • 7.3.1. Company Overview
    • 7.3.2. Financial Information
    • 7.3.3. Vector Manufacturing Technology Portfolio
    • 7.3.4. Manufacturing Facilities
    • 7.3.5. Future Outlook
  • 7.4. bluebird bio
    • 7.4.1. Company Overview
    • 7.4.2. Financial Information
    • 7.4.3. Manufacturing Facilities
    • 7.4.4. Manufacturing Experience
    • 7.4.5. Future Outlook
  • 7.5. Brammer Bio
    • 7.5.1. Company Overview
    • 7.5.2. Manufacturing Facilities
    • 7.5.3. Manufacturing Experience
    • 7.5.4. Future Outlook
  • 7.6. FUJIFILM Diosynth Biotechnologies
    • 7.6.1. Company Overview
    • 7.6.2. Financial Information
    • 7.6.3. Manufacturing Facilities
    • 7.6.4. Manufacturing Experience
    • 7.6.5. Future Outlook
  • 7.7. MassBiologics
    • 7.7.1. Company Overview
    • 7.7.2. Manufacturing Facilities
    • 7.7.3. Future Outlook
  • 7.8. Novasep
    • 7.8.1. Company Overview
    • 7.8.2. Financial Information
    • 7.8.3. Manufacturing Facilities
    • 7.8.4. Manufacturing Experience
    • 7.8.5. Future Outlook
  • 7.9. Spark Therapeutics
    • 7.9.1. Company Overview
    • 7.9.2. Financial Information
    • 7.9.3. Manufacturing Facilities
    • 7.9.4. Vector Manufacturing Technology Portfolio
    • 7.9.5. Manufacturing Experience
    • 7.9.6. Future Outlook
  • 7.10. Vigene Biosciences
    • 7.10.1. Company Overview
    • 7.10.2. Manufacturing Facilities
    • 7.10.3. Vector Manufacturing Technology Portfolio
    • 7.10.4. Manufacturing Experience
    • 7.10.5. Future Outlook

8. VECTOR AND GENE THERAPY MANUFACTURERS IN EUROPE

  • 8.1. Chapter Overview
  • 8.2. Biovian
    • 8.2.1. Company Overview
    • 8.2.2. Manufacturing Facilities
    • 8.2.3. Future Outlook
  • 8.3. Cell and Gene Therapy Catapult
    • 8.3.1. Company Overview
    • 8.3.2. Manufacturing Facilities
    • 8.3.3. Future Outlook
  • 8.4. Cobra Biologics
    • 8.4.1. Company Overview
    • 8.4.2. Financial Performance
    • 8.4.3. Manufacturing Facilities
    • 8.4.4. Vector Manufacturing Technology Portfolio
    • 8.4.5. Manufacturing Experience
    • 8.4.6. Future Outlook
  • 8.5. FinVector
    • 8.5.1. Company Overview
    • 8.5.2. Manufacturing Facilities
    • 8.5.3. Viral Vector Manufacturing Technology
    • 8.5.4. Future Outlook
  • 8.6. Kaneka Eurogentec
    • 8.6.1. Company Overview
    • 8.6.2. Manufacturing Facilities
    • 8.6.3. Manufacturing Experience
    • 8.6.4. Future Outlook
  • 8.7. Lonza
    • 8.7.1. Company Overview
    • 8.7.2. Financial Information
    • 8.7.3. Vector Manufacturing Technology Portfolio
    • 8.7.4. Manufacturing Facilities
    • 8.7.5. Future Outlook
  • 8.8. MolMed
    • 8.8.1. Company Overview
    • 8.8.2. Financial Information
    • 8.8.3. Manufacturing Facilities
    • 8.8.4. Manufacturing Experience
    • 8.8.5. Future Outlook
  • 8.9. Oxford BioMedica
    • 8.9.1. Company Overview
    • 8.9.2. Financial Information
    • 8.9.3. Manufacturing Facilities
    • 8.9.4. Vector Manufacturing Technology Portfolio
    • 8.9.5. Manufacturing Experience
    • 8.9.6. Future Outlook
  • 8.10. Richter-Helm
    • 8.10.1. Company Overview
    • 8.10.2. Manufacturing Facilities
    • 8.10.3. Future Outlook
  • 8.11. Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
    • 8.11.1. Company Overview
    • 8.11.2. Financial Information
    • 8.11.3. Manufacturing Facilities
    • 8.11.4. Manufacturing Experience
    • 8.11.5. Future Outlook
  • 8.12. uniQure
    • 8.12.1. Company Overview
    • 8.12.2. Financial Information
    • 8.12.3. Manufacturing Facilities
    • 8.12.4. Vector Manufacturing Technology Portfolio
    • 8.12.5. Future Outlook
  • 8.13. VIVEbiotech
    • 8.13.1. Company Overview
    • 8.13.2. Vector Manufacturing Technology Portfolio
    • 8.13.3. Manufacturing Facilities
    • 8.13.4. Future Outlook

9. VECTOR AND GENE THERAPY MANUFACTURERS IN ASIA-PACIFIC

  • 9.1. Chapter Overview
  • 9.2. Wuxi AppTec
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Manufacturing Facilities
    • 9.2.4. Manufacturing Experience
    • 9.2.5. Future Outlook
  • 9.3. Other Key Players

10. EMERGING VECTORS

  • 10.1. Chapter Overview
    • 10.1.1. Alphavirus Based Vectors
    • 10.1.2. Anc80 Based Vectors
    • 10.1.3. Bifidobacterium longum Based Vectors
    • 10.1.4. Cytomegalovirus Based Vectors
    • 10.1.5. Listeria monocytogenes Based Vectors
    • 10.1.6. Minicircle DNA Based Vectors
    • 10.1.7. Modified Vaccinia Ankara Based Vectors
    • 10.1.8. Myxoma Virus Based Vectors
    • 10.1.9. Self-Complementary Vectors
    • 10.1.10. Sendai Virus Based Vectors
    • 10.1.11. Sleeping Beauty Transposons

11. RECENT COLLABORATIONS AND PARTNERSHIPS

  • 11.1. Chapter Overview
  • 11.2. Partnership Models
  • 11.3. Vector and Gene Therapy Manufacturing: Recent Collaborations and Partnerships
    • 11.3.1. Analysis by Year of Partnership
    • 11.3.2. Analysis by Type of Partnership
    • 11.3.3. Analysis by Type of Vector
    • 11.3.4. Analysis by Scale of Operation
    • 11.3.5. Most Active Players: Analysis by Number of Partnerships
    • 11.3.6. Regional Analysis
      • 11.3.6.1. Most Active Players in Different Geographical Regions
      • 11.3.6.2. Intercontinental and Intracontinental Agreements
  • 11.4. Other Collaborations

12. KEY INSIGHTS

  • 12.1. Chapter Overview
  • 12.2. Vector and Gene Therapy Manufacturers: Analysis of Competitive Landscape by Purpose of Production, Type of Vector and Scale of Operation
  • 12.3. Vector and Gene Therapy Manufacturers: Analysis by Company Size and Type of Vector
  • 12.4. Vector and Gene Therapy Manufacturers: Prominent Geographical Hubs by Type of Organization
    • 12.4.1. Contract Manufacturers
    • 12.4.2. In-House Manufacturers
  • 12.5. Vector and Gene Therapy Manufacturers: Analysis by Location of Manufacturing Facilities and Type of Vector
    • 12.5.1. AAV Vector Manufacturers
    • 12.5.2. Adenoviral Vector Manufacturers
    • 12.5.3. Lentiviral Vector Manufacturers
    • 12.5.4. Retroviral Vector Manufacturers
    • 12.5.5. Plasmid DNA Manufacturers

13. VIRAL VECTOR AND PLASMID DNA COST PRICE ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Factors Contributing to High Price of Viral Vector and Plasmid DNA Based Therapies
  • 13.3. Viral Vector and Plasmid DNA Based Therapies: Pricing Models
    • 13.3.1. On the Basis of Expert Opinions
    • 13.3.2. On the Basis of Manufacturing Cost
      • 13.3.2.1. On the Basis of Technology Used
      • 13.3.2.2. On the Basis of Scale of Manufacturing
      • 13.3.2.3. On the Basis of Client Type
    • 13.3.3. Prices of Different Types of Vectors
  • 13.4. Concluding Remarks

14. CAPACITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. Installed, Global Viral Vector Manufacturing Capacity
    • 14.3.1. Analysis by Company Size
    • 14.3.2. Analysis by Location of Manufacturing Facilities
    • 14.3.3. Analysis by Scale of Operation
  • 14.4. Installed, Global Plasmid DNA Manufacturing Capacity
    • 14.4.1. Analysis by Company Size
    • 14.4.2. Analysis by Location of Manufacturing Facilities
    • 14.4.3. Analysis by Scale of Operation
  • 14.5. Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity
  • 14.6. Concluding Remarks

15. DEMAND ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Assumptions and Methodology
  • 15.3. Global, Clinical Demand for Viral Vector and Plasmid DNA
    • 15.3.1. Analysis by Geographical Location
    • 15.3.2. Analysis by Type of Vector
    • 15.3.3. Analysis by Type of Therapy
  • 15.4. Global, Commercial Demand for Viral Vector and Plasmid DNA
    • 15.4.1. Analysis by Geographical Location
    • 15.4.2. Analysis by Type of Vector
    • 15.4.3. Analysis by Type of Therapy
  • 15.5. Demand and Supply Analysis
  • 15.6. Concluding Remarks

16. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Scope of the Forecast
  • 16.3. Input Tables and Key Assumptions
  • 16.4. Forecast Methodology
  • 16.5. Overall Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030
    • 16.5.1. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Type of Vector
      • 16.5.1.1. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Market Attractiveness by Type of Vector
    • 16.5.2. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Application Area
    • 16.5.3. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Therapeutic Area
    • 16.5.4. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Scale of Operation
    • 16.5.5. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Purpose of Production
    • 16.5.6. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Geography
  • 16.6. Current and Future Market Opportunity from Commercial Products
    • 16.6.1. AAV Vectors
      • 16.6.1.1. AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
      • 16.6.1.2. AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area
      • 16.6.1.3. AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography
    • 16.6.2. Adenoviral Vectors
      • 16.6.2.1. Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
      • 16.6.2.2. Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area
      • 16.6.2.3. Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography
    • 16.6.3. Lentiviral Vectors
      • 16.6.3.1. Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
      • 16.6.3.2. Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area
      • 16.6.3.3. Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography
    • 16.6.4. Retroviral Vectors
      • 16.6.4.1. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
      • 16.6.4.2. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area
      • 16.6.4.3. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography
    • 16.6.5. Plasmid DNA
      • 16.6.5.1. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
      • 16.6.5.2. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area
      • 16.6.5.3. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography
    • 16.6.6. Other Viral and Non-Viral Vectors
  • 16.7. Opportunity from Clinical Candidates
    • 16.7.1. AAV Vectors
      • 16.7.1.1. AAV Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
      • 16.7.1.2. AAV Vector Manufacturing Market for Clinical Products, 2019-2030: Distribution by Phase of Development
      • 16.7.1.3. AAV Vector Manufacturing Market for Clinical Products, 2019-2030: Distribution by Geography
    • 16.7.2. Adenoviral Vectors
      • 16.7.2.1. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
      • 16.7.2.2. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development
      • 16.7.2.3. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography
    • 16.7.3. Lentiviral Vectors
      • 16.7.3.1. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
      • 16.7.3.2. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development
      • 16.7.3.3. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography
    • 16.7.4. Retroviral Vectors
      • 16.7.4.1. Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
      • 16.7.4.2. Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development
      • 16.7.4.3. Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography
    • 16.7.5. Plasmid DNA
      • 16.7.5.1. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
      • 16.7.5.2. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development
      • 16.7.5.3. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography
    • 16.7.6. Other Viral and Non-Viral Vectors
  • 16.8. Opportunity from Preclinical Candidates
    • 16.8.1. AAV Vectors
      • 16.8.1.1. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
      • 16.8.1.2. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area
      • 16.8.8.3. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
      • 16.8.1.4. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography
    • 16.8.2. Adenoviral Vectors
      • 16.8.2.1. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
      • 16.8.2.2. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area
      • 16.8.2.3. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
      • 16.8.2.4. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography
    • 16.8.3. Lentiviral Vectors
      • 16.8.3.1. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
      • 16.8.3.2. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area
      • 16.8.3.3. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
      • 16.8.3.4. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography
    • 16.8.4. Retroviral Vectors
      • 16.8.4.1. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
      • 16.8.4.2. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area
      • 16.8.4.3. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
      • 16.8.4.4. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography
    • 16.8.5. Plasmid DNA
      • 16.8.5.1. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
      • 16.8.5.2. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area
      • 16.8.5.3. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
      • 16.8.5.4. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography
    • 16.8.6. Other Viral and Non-Viral Vectors

17. KEY DRIVERS AND CHALLENGES

  • 17.1. Chapter Overview
  • 17.2. Viral Vector and Plasmid DNA Manufacturing Market: Drivers and Challenges
    • 17.2.1. AAV Vectors
    • 17.2.2. Adenoviral Vectors
    • 17.2.3. Lentiviral Vectors
    • 17.2.4. Retroviral Vectors
    • 17.2.5. Plasmid DNA
  • 17.3. Concluding Remarks

18. SURVEY ANALYSIS

  • 18.1. Chapter Overview
  • 18.2. Seniority Level of Respondents
  • 18.3. Type of Vector
  • 18.4. Scale of Production
  • 18.5. Vector Stabilization Technology
  • 18.6. In-house / Contract Operations

19. CONCLUDING REMARKS

20. EXECUTIVE INSIGHTS

  • 20.1. Chapter Overview
  • 20.2. Batavia Biosciences
    • 20.2.1. Company Snapshot
    • 20.2.2. Interview Transcript: Menzo Havenga, Chief Executive Officer and President
  • 20.3. CEVEC Pharmaceuticals
    • 20.3.1. Company Snapshot
    • 20.3.2. Interview Transcript: Nicole Faust, Chief Executive Officer & Chief Scientific Officer
  • 20.4. Vigene Biosciences
    • 20.4.1. Company Snapshot
    • 20.4.2. Interview Transcript: Jeffrey Hung, Chief Commercial Officer
  • 20.5. Clean Cells
    • 20.5.1. Company Snapshot
    • 20.5.2. Interview Transcript: Laurent Ciavatti, Business Development Manager, Olivier Boisteau, Co-Founder / President and Xavier Leclerc, Head of Gene Therapy
  • 20.6. Amsterdam BioTherapeutics Unit (AmBTU)
    • 20.6.1. Company Snapshot
    • 20.6.2. Interview Transcript: Joost van den Berg, Director
  • 20.7. MGH Viral Vector Development Facility, Massachusetts General Hospital
    • 20.7.1. Company Snapshot
    • 20.7.2. Interview Transcript: Bakhos A Tannous, Director
  • 20.8. CJ PARTNERS
    • 20.8.1. Company Snapshot
    • 20.8.2. Interview Transcript: Interview Transcript, Colin Lee Novick, Managing Director
  • 20.9. Delphi Genetics
    • 20.9.1. Company Snapshot
    • 20.9.2. Interview Transcript: Cedric Szpirer, Executive & Scientific Director
  • 20.10. ACGT
    • 20.10.1. Company Snapshot
    • 20.10.2. Interview Transcript: Semyon Rubinchik, Scientific Director
  • 20.11. Novasep
    • 20.11.1. Company Snapshot
    • 20.11.2. Interview Transcript: Alain Lamproye, President of Biopharma Business Unit
  • 20.12. Richter-Helm
    • 20.12.1. Company Snapshot
    • 20.12.2. Interview Transcript: Astrid Brammer, Senior Manager Business Development
  • 20.13. Waisman Biomanufacturing
    • 20.13.1. Company Snapshot
    • 20.13.2. Interview Transcript: Brian M Dattilo, Business Development Manager
  • 20.14. Plasmid Factory
    • 20.14.1. Company Snapshot
    • 20.14.2. Interview Transcript: Marco Schmeer, Project Manager and Tatjana Buchholz, Marketing Manager
  • 20.15. GEG Tech
    • 20.15.1. Company Snapshot
    • 20.15.2. Interview Transcript: Nicolas Grandchamp, R&D Leader

21. APPENDIX I: TABULATED DATA

22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1. Gene Transfer: Viral and Non-Viral Methods
  • Figure 3.2. Vector Manufacturing: Types of Manufacturers
  • Figure 3.3. Viral Vectors: Manufacturing Process
  • Figure 4.1. Viral Vector and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Establishment
  • Figure 4.2. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
  • Figure 4.3. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters
  • Figure 4.4. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities
  • Figure 4.5. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
  • Figure 4.6. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
  • Figure 4.7. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector
  • Figure 4.8. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
  • Figure 4.9. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
  • Figure 5.1. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Establishment
  • Figure 5.2. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
  • Figure 5.3. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters
  • Figure 5.4. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities
  • Figure 5.5. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
  • Figure 5.6. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
  • Figure 5.7. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
  • Figure 5.8. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
  • Figure 6.1. Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
  • Figure 6.3. Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Manufacturing Facilities
  • Figure 6.5. Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
  • Figure 6.6. Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Production
  • Figure 6.7. Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
  • Figure 7.1. SAFC Commercial: Revenues, 2011- Q3 2015 (USD Million)
  • Figure 7.2. H.A.V.E.: AAV Vector Manufacturing Technology
  • Figure 7.3. bluebird bio: Revenues, 2014-2018 (USD Million)
  • Figure 7.4. bluebird bio Viral Vectors: Stages of Manufacturing Process
  • Figure 7.5. FUJIFILM Holdings: Revenues, 2014-2018 (JPY Billion)
  • Figure 7.6. Novasep: Revenues, 2013-2017 (EUR Million)
  • Figure 7.7. Novasep: Viral Vector Manufacturing Process
  • Figure 7.8. Spark Therapeutics: Revenues, 2014-2018 (USD Million)
  • Figure 8.1. Lonza: Revenues, 2014- H1 2019 (CHF Million)
  • Figure 8.2. MolMed: Revenues, 2014-H1 2019 (EUR Million)
  • Figure 8.3. Oxford BioMedica: Revenues, 2014-2018 (GBP Million)
  • Figure 8.4. Sanofi: Revenues, 2014-H1 2019 (EUR Billion)
  • Figure 8.5. uniQure: Revenues, 2014- 2018 (USD Million)
  • Figure 9.1. Wuxi Biologics: Revenues, 2014-H1 2019 (USD Million)
  • Figure 11.1. Vector and Gene Therapy Partnerships: Cumulative Year-wise Trend (2015-2019)
  • Figure 11.2. Vector and Gene Therapy Partnerships: Distribution by Type
  • Figure 11.3. Vector and Gene Therapy Partnerships: Distribution by Type of Vector
  • Figure 11.4. Vector and Gene Therapy Partnerships: Distribution by Scale of Operation
  • Figure 11.5. Vector and Gene Therapy Partnerships: Most Active Players
  • Figure 11.6. Vector and Gene Therapy Partnerships: Regional Distribution and Most Active Players
  • Figure 11.7. Vector and Gene Therapy Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
  • Figure 12.1. Vector and Gene Therapy Manufacturers: Competitive Landscape by Purpose of Production, Type of Vector and Scale of Operation
  • Figure 12.2. Vector and Gene Therapy Manufacturers: Logo Landscape by Company Size and Type of Vector
  • Figure 12.3. Vector and Gene Therapy Contract Manufacturers: Prominent Geographical Hubs
  • Figure 12.4. Vector and Gene Therapy In-House Manufacturers: Prominent Geographical Hubs
  • Figure 12.5. AAV Vector Manufacturers: Distribution by Location of Manufacturing Facilities
  • Figure 12.6. Adenoviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
  • Figure 12.7. Lentiviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
  • Figure 12.8. Retroviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
  • Figure 12.9. Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facilities
  • Figure 14.1. Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
  • Figure 14.2. Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
  • Figure 14.3. Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size
  • Figure 14.4. Installed, Global Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity
  • Figure 14.5. Installed, Global Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Manufacturing Facilities
  • Figure 14.6. Installed, Global Viral Vector Manufacturing Capacity: Distribution by Scale of Operation
  • Figure 14.7. Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size
  • Figure 14.8. Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity
  • Figure 14.9. Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facilities
  • Figure 14.10. Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Scale of Operation
  • Figure 14.11. Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Geographical Location of Manufacturing Facilities
  • Figure 14.12. Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector
  • Figure 15.1. Global Clinical Demand for Viral Vector and Plasmid DNA
  • Figure 15.2. Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location
  • Figure 15.3. Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector
  • Figure 15.4. Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy
  • Figure 15.5. Global Commercial Demand for Viral Vector and Plasmid DNA
  • Figure 15.6. Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location
  • Figure 15.7. Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector
  • Figure 15.8. Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy
  • Figure 15.9. Demand and Supply Distribution
  • Figure 16.1. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030 (USD Billion)
  • Figure 16.2. Viral Vector and Plasmid DNA Manufacturing, 2019-2030: Distribution by Type of Vector (USD Million)
  • Figure 16.3. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Market Attractiveness Analysis by Type of Vector
  • Figure 16.4. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.5. Viral Vector and Plasmid DNA Manufacturing Market, 2020, 2025 and 2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.6. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Million)
  • Figure 16.7. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Purpose of Production (USD Million)
  • Figure 16.8. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.9. AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.10. AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.11. AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.12. Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.13. Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.14. Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.15. Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.16. Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.17. Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.18. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.19. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.20. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.21. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.22. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.23. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.24. Other Vector Manufacturing Market for Commercial Products, 2019-2030 (USD Million)
  • Figure 16.25. AAV Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.26. AAV Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
  • Figure 16.27. AAV Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.28. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.29. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
  • Figure 16.30. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.31. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.32. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
  • Figure 16.33. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.34. Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.35. Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
  • Figure 16.36. Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.37. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.38. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
  • Figure 16.39. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.40. Other Vector Manufacturing Market for Clinical Candidates, 2019-2030 (USD Million)
  • Figure 16.41. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.42. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.43. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
  • Figure 16.44. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.45. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.46. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.47. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
  • Figure 16.48. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.49. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.50. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.51. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
  • Figure 16.52. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.53. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.54. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.55. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
  • Figure 16.56. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.57. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Figure 16.58. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area USD Million)
  • Figure 16.59. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
  • Figure 16.60. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Figure 16.61. Other Vectors Manufacturing Market for Preclinical Candidates, 2019-2030 (USD Million)
  • Figure 17.1. AAV Vectors: Drivers and Challenges
  • Figure 17.2. Adenoviral Vectors: Drivers and Challenges
  • Figure 17.3. Lentiviral Vectors: Drivers and Challenges
  • Figure 17.4. Retroviral Vectors: Drivers and Challenges
  • Figure 17.5. Plasmid DNA: Drivers and Challenges
  • Figure 18.1. Survey Analysis: Distribution by Type of Organization
  • Figure 18.2. Survey Analysis: Distribution by Geographical Location of Organization
  • Figure 18.3. Survey Analysis: Distribution by Seniority Level of Respondents
  • Figure 18.4. Survey Analysis: Distribution by Type of Vector
  • Figure 18.5. Survey Analysis: Distribution by Scale of Production
  • Figure 18.6. Survey Analysis: Vector Stabilization Technology
  • Figure 18.7. Survey Analysis: Distribution by Purpose of Production (In-house Production versus Contract Services)

List of Tables

  • Table 3.1. Viral Vectors: Key Features
  • Table 3.2. Small Scale Cell Culture Systems
  • Table 4.1. Viral Vector and Gene Therapy Manufacturers: List of Industry Players
  • Table 4.2. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Type of Viral Vector
  • Table 4.3. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Scale of Production
  • Table 4.4. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Application Area
  • Table 5.1. Plasmid DNA and Gene Therapy Manufacturers: List of Industry Players
  • Table 5.2. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Scale of Production
  • Table 5.3. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Application Area
  • Table 6.1. Vector and Gene Therapy Manufacturers: List of Non-Industry Players
  • Table 6.2. Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Scale of Production
  • Table 6.3. Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Application Area
  • Table 7.1. Vector and Gene Therapy Production in North America: List of Profiled Companies
  • Table 7.2. Aldevron Plasmid DNA: QC Assays
  • Table 7.3. Aldevron: Future Outlook
  • Table 7.4. BioReliance / SAFC Commercial (Merck KGaA): Future Outlook
  • Table 7.5. bluebird bio: Future Outlook
  • Table 7.6. Brammer Bio: Future Outlook
  • Table 7.7. FUJIFILM Diosynth Biotechnologies: Future Outlook
  • Table 7.8. MassBiologics: Future Outlook
  • Table 7.9. Novasep Viral Vectors: Manufacturing Experience
  • Table 7.10. Novasep: Future Outlook
  • Table 7.11. Spark Therapeutics: Future Outlook
  • Table 7.12. Vigene Biosciences: Future Outlook
  • Table 8.1. Vector and Gene Therapy Production in Europe: List of Players Profiled
  • Table 8.2. Biovian: Future Outlook
  • Table 8.3. Cell and Gene Therapy Catapult: Future Outlook
  • Table 8.4. Cobra Biologics: Future Outlook
  • Table 8.5. FinVector Manufacturing Suites: Features
  • Table 8.6. FinVector: Future Outlook
  • Table 8.7. Kaneka Eurogentec: Future Outlook
  • Table 8.8. Lonza: Future Outlook
  • Table 8.9. MolMed: Future Outlook
  • Table 8.10. Oxford BioMedica: Future Outlook
  • Table 8.11. Richter-Helm: Future Outlook
  • Table 8.12. Sanofi (CEPiA, Sanofi Pasteur, Genzyme): Future Outlook
  • Table 8.13. uniQure: Future Outlook
  • Table 8.14. VIVEbiotech: Future Outlook
  • Table 9.1. Vector and Gene Therapy Manufacturers: List of Key Players based in Asia Pacific
  • Table 9.2. Wuxi AppTec: Future Outlook
  • Table 11.1. Vector and Gene Therapy Manufacturing: List of Partnerships
  • Table 11.2. Vector and Gene Therapy Manufacturing Partnerships: Most Active Players
  • Table 11.3. Vector and Gene Therapy Manufacturing: List of Other Partnerships
  • Table 13.1. Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions / Primary Research
  • Table 13.2. Viral Vector and Plasmid DNA: Prices of Vectors
  • Table 14.1. Installed, Global Viral Vector Manufacturing Capacity: Sample Data Set
  • Table 14.2. Installed, Global Plasmid DNA Manufacturing Capacity: Sample Data Set
  • Table 14.3. Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size
  • Table 14.4. Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size
  • Table 15.1. Demand Analysis: List of Approved Cell and Gene Therapies
  • Table 16.1. Viral Vector and Plasmid DNA: Active Clinical Studies
  • Table 16.2. Viral Vector and Plasmid DNA: Distribution by Patients Enrolled in the Active Clinical Studies
  • Table 16.3. Viral Vector and Plasmid DNA: Number of Active Clinical Trials, 2019-2030
  • Table 16.4. Viral Vector and Plasmid DNA: Number of Patients Enrolled in Active Clinical Trials, 2019-2030
  • Table 16.5. Viral Vector and Plasmid DNA: Approved / Late-Stage Genetically Modified Therapies
  • Table 18.1. Survey Response: Overview of the Participating Companies / Organizations
  • Table 18.2. Survey Response: Seniority Level of Respondents
  • Table 18.3. Survey Response: Type of Vector
  • Table 18.4. Survey Response: Scale of Production
  • Table 18.5. Survey Response: Vector Stabilization Technology
  • Table 18.6. Survey Response: Purpose of Production (In-house Production versus Contract Services)
  • Table 20.1. CEVEC Pharmaceuticals: Key Highlights
  • Table 20.2. Clean Cells: Key Highlights
  • Table 20.3. Amsterdam BioTherapeutics Unit (AmBTU): Key Highlights
  • Table 20.4. MGH Viral Vector Development Facility, Massachusetts General Hospital: Key Highlights
  • Table 20.5. CJ PARTNERS Key Highlights
  • Table 20.6. Delphi Genetics: Key Highlights
  • Table 20.7. ACGT: Key Highlights
  • Table 20.8. Waisman Biomanufacturing: Key Highlights
  • Table 20.9. PlasmidFactory: Key Highlights
  • Table 20.10. GEG Tech: Key Highlights
  • Table 21.1. Viral Vector and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Establishment
  • Table 21.2. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
  • Table 21.2. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters
  • Table 21.3. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities
  • Table 21.4. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
  • Table 21.5. Viral Vector Manufacturers and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
  • Table 21.6. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector
  • Table 21.7. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
  • Table 21.8. Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
  • Table 21.9. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Establishment
  • Table 21.10. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
  • Table 21.10. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters
  • Table 21.11. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities
  • Table 21.12. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
  • Table 21.13. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
  • Table 21.14. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
  • Table 21.15. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
  • Table 21.16. Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
  • Table 21.17. Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities
  • Table 21.18. Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
  • Table 21.19. Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Production
  • Table 21.20. Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
  • Table 21.21. SAFC: Revenues, 2011-Q3 2015 (USD Million)
  • Table 21.22. bluebird bio: Revenues, 2014-2018 (USD Million)
  • Table 21.23. FUJIFILM Holdings: Revenues, 2014-2018(JPY Billion)
  • Table 21.24. Novasep: Revenues, 2013-2017 (EUR Million)
  • Table 21.25. Spark Therapeutics: Revenues, 2014-2018 (USD Million)
  • Table 21.26. Lonza: Revenues, 2014-H1 2019 (CHF Million)
  • Table 21.27. MolMed: Revenues, 2014-H1 2019 (EUR Million)
  • Table 21.28. Oxford BioMedica: Revenues, 2014-2018 (GBP Million)
  • Table 21.29. Sanofi: Revenues, 2014-H1 2019 (EUR Billion)
  • Table 21.30. uniQure: Revenues, 2014-2018 (USD Million)
  • Table 21.31. Wuxi Biologics: Revenues, 2014-H1 2019 (USD Million)
  • Table 21.32. Vector and Gene Therapy Partnerships: Cumulative Year-wise Trend (2015- 2019)
  • Table 21.33. Vector and Gene Therapy Partnerships: Distribution by Type
  • Table 21.34. Vector and Gene Therapy Partnerships: Distribution by Type of Vector
  • Table 21.35. Vector and Gene Therapy Partnerships: Distribution by Scale of Operation
  • Table 21.36. Vector and Gene Therapy Partnerships: Most Active Players
  • Table 21.37. Vector and Gene Therapy Partnerships: Regional Distribution and Most Active Players
  • Table 21.38. Vector and Gene Therapy Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
  • Table 21.39. Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
  • Table 21.40. Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
  • Table 21.41. Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size
  • Table 21.42. Installed, Global Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity
  • Table 21.42. Installed, Global Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Manufacturing Facilities
  • Table 21.43. Installed, Global Viral Vector Manufacturing Capacity: Distribution by Scale of Operation
  • Table 21.45. Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size
  • Table 21.46. Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity
  • Table 21.47. Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Geographical Location of Manufacturing Facilities
  • Table 21.48. Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Scale of Operation
  • Table 21.49. Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector
  • Table 21.50. Global Clinical Demand for Viral Vector and Plasmid DNA
  • Table 21.51. Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location
  • Table 21.52. Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector
  • Table 21.53. Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy
  • Table 21.54. Global Commercial Demand for Viral Vector and Plasmid DNA
  • Table 21.55. Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location
  • Table 21.56. Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector
  • Table 21.57. Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy
  • Table 21.58. Demand and Supply Distribution
  • Table 21.59. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030 (USD Billion)
  • Table 21.60. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Type of Vector (USD Million)
  • Table 21.61. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.62. Viral Vector and Plasmid DNA Manufacturing Market, 2020, 2025 and 2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.63. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.64. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Purpose of Production (USD Million)
  • Table 21.65. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.66. AAV Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.67. AAV Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.68. AAV Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.69. Adenoviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.70. Adenoviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.71. Adenoviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.72. Lentiviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.73. Lentiviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.74. Lentiviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.75. Retroviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.76. Retroviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.77. Retroviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.78. Plasmid DNA Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.79. Plasmid DNA Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.80. Plasmid DNA Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.81. Other Viral Vector Manufacturing Market for Commercial Products, 2019-2030 (USD Million)
  • Table 21.82. AAV Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.83. AAV Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
  • Table 21.84. AAV Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.85. Adenoviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.86. Adenoviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
  • Table 21.87. Adenoviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.88. Lentiviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.89. Lentiviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
  • Table 21.90. Lentiviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.91. Retroviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.92. Retroviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
  • Table 21.93. Retroviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.94. Plasmid DNA Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.95. Plasmid DNA Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
  • Table 21.96. Plasmid DNA Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.97. Other Viral Vectors Manufacturing Market for Clinical Candidates, 2019-2030 (USD Million)
  • Table 21.98. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.99. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.100. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
  • Table 21.101. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.102. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.103. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.104. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
  • Table 21.105. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.106. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.107. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.108. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
  • Table 21.109. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.110. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.111. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.112. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
  • Table 21.113. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.114. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
  • Table 21.115. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.116. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
  • Table 21.117. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
  • Table 21.118. Other Vector Manufacturing Market for Preclinical Candidates, 2019-2030 (USD Million)
  • Table 21.119. Survey Analysis: Distribution by Type of Organization
  • Table 21.120. Survey Analysis: Distribution by Geographical Location of Organization
  • Table 21.121. Survey Analysis: Distribution by Seniority Level of Respondents
  • Table 21.122. Survey Analysis: Distribution by Type of Vector
  • Table 21.123. Survey Analysis: Distribution by Scale of Production
  • Table 21.124. Survey Analysis: Vector Stabilization Technology
  • Table 21.125. Survey Analysis: Distribution by Purpose of Production (In-house Production versus Contract Services)

List of Companies

The following companies and organizations have been mentioned in the report.

  • 4D Molecular Therapeutics
  • AbbVie
  • Abeona Therapeutics
  • Acucela
  • Adaptimmune Therapeutics
  • Addgene
  • Aduro Biotech
  • Advanced BioScience Laboratories (ABL)
  • Advanced Biotherapeutics Consulting
  • Advaxis
  • ADVENT
  • Adverum Biotechnologies (previously known as Avalanche Biotechnologies)
  • Agenzia Italiana del Farmaco
  • Agilent Technologies
  • Agilis Biotherapeutics
  • Aldevron
  • Allele Biotechnology
  • Alma Bio Therapeutics
  • AlphaVax
  • Althea Technologies
  • American Gene Technologies
  • Amgen
  • AMSBIO
  • Amsterdam BioTherapeutics Unit (AmBTU)
  • Anaeropharma Science
  • Anemocyte
  • apceth Biopharma
  • Applied Biological Materials (ABM)
  • Applied Genetic Technologies (AGTC)
  • Applied Viromics
  • ARCO Design/Build
  • Areta International
  • Asklepios BioPharmaceutical
  • Atlantic Bio GMP
  • ATVIO Biotech
  • Audentes Therapeutics
  • Autolus
  • AveXis
  • Avista Capital Partners
  • AVROBIO
  • Bamboo Therapeutics
  • Batavia Biosciences
  • Bavarian Nordic
  • Baxter
  • Beckman Research Institute
  • Belfer Gene Therapy Core Facility, Cornell University
  • Belfer Gene Therapy Core Facility, Cornell University
  • Benitec Biopharma
  • BioCancell
  • Biogen
  • Biomay
  • Biomiga
  • BioNTech Innovative Manufacturing Service (previously known as Eufects)
  • BioReliance
  • Biotec Services International
  • Biotechnology Department of San Raffaele
  • Biotherapeutics Development Unit, Cancer Research UK
  • Biotie Therapies
  • Bioverativ
  • BioVex
  • Biovian
  • Blue Sky BioServices
  • Bluebird Bio (previously known as Genetix Pharmaceuticals)
  • B-MoGen Biotechnologies
  • Boehringer Ingelheim BioXcellence™
  • Brammer Bio (now a part of Thermo Fisher Scientific)
  • Brazilian Biosciences National Laboratory (LNBio)
  • BRC Clinical Research Facility and Cell Therapy Unit, King's College London
  • Brewin Dolphin
  • Bristol-Myers Squibb
  • Brookside Capital
  • California Institute for Regenerative Medicine
  • California Institute of Technology
  • Calimmune
  • Cancer Research UK
  • Capsugel
  • Carnegie Institution for Science
  • Celgene
  • Cell and Gene Therapy Catapult
  • Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
  • Celladon
  • Cellectis
  • Cellular Biomedicine Group
  • Celonic
  • Center for Biomedicine & Genetics, City of Hope
  • Center for Cell & Gene Therapy, Baylor College of Medicine
  • Center for Cell and Gene Processing, Takara Bio
  • Centre for Cell and Vector Production, Centre for Commercialization of Regenerative Medicine
  • CEVEC Pharmaceuticals
  • Chiesi Farmaceutici
  • Children's GMP, St. Jude Children's Research Hospital
  • Children's Hospital of Philadelphia
  • CIEMAT
  • Cincinnati Children's Hospital Medical Center
  • Clean Cells
  • Clinical Biotechnology Centre, NHS Blood and Transplant
  • Clinical Vector Production Core, University of Pittsburgh
  • Cobra Biologics
  • CombiGene
  • Core Facility for Therapeutic Vectors, Institute of Medical Science Research Hospital
  • Cranfield University
  • Creative Biogene
  • Creative Biolabs
  • Creed Commercial Development
  • Cytovance Biologics
  • Deerfield Management
  • Delphi Genetics
  • Department of Neuroscience, University of Minnesota
  • Desktop Genetics
  • Division of Human Gene Therapy, Stanford University
  • DNAtrix
  • Elixirgen Scientific
  • Emergent BioSolutions
  • Epeius Biotechnologies
  • EUFETS
  • Eurofins Genomics
  • Eurofins Scientific
  • European Society of Gene and Cell Therapy
  • ExcellGene
  • Finnish Bioindustries
  • FinVector (previously known as Ark Therapeutics)
  • Fisher BioServices
  • Five Prime Therapeutics
  • FKD Therapies
  • Flash Therapeutics
  • Florida Biologix
  • Fondazione Telethon
  • Foundation Fighting Blindness
  • Fraunhofer Institute for Toxicology and Experimental Medicine
  • Freeline Therapeutics
  • FUJIFILM Diosynth Biotechnologies
  • GE Healthcare
  • GEG Tech
  • Genable Technologies
  • Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  • Gene Editing and Viral Vector Core, City of Hope
  • Gene Editing and Viral Vector Core, City of Hope
  • Gene Medicine Japan
  • Gene Silencing and Expression Facility, Robinson Research Institute, University of Adelaide
  • Gene Therapy Clinical Vector Production Core, University of Pittsburgh
  • Gene Therapy Research Institute
  • Gene Transfer Vector Core, Grousbeck Gene Therapy Center
  • Gene Transfer Vector Core, Schepens Eye Research Institute
  • Gene Transfer, Targeting and Therapeutics Core, Salk Institute for Biological Studies
  • GeneCure Biotechnologies
  • GeneDetect
  • GeneImmune Biotechnology
  • Genethon
  • GENEWIZ
  • GenIbet Biopharmaceuticals
  • GenScript
  • GenVec
  • Genzyme
  • GIGA Institute, Liege Universite
  • Gilead Sciences
  • GlaxoSmithKline
  • Green Cross LabCell
  • Guy's Hospital, London
  • Hercules Capital
  • Hong Kong Institute of Biotechnology
  • Hookipa Biotech
  • Hope Center Viral Vectors Core, Washington University School of Medicine
  • Horizon Discovery
  • Hospital de Sant Pau
  • Human Gene and Cell Therapy Center, Akdeniz University
  • Human Stem Cells Institute
  • ID Pharma (previously known as DNAVEC)
  • Immune Design
  • Immune Technology
  • ImmunoGenes
  • Immunomic Therapeutics
  • Inbiomed
  • Indiana University Vector Production Facility
  • Instituto de Tecnologia Química e Biológica António Xavier
  • Intrexon
  • InvivoGen
  • IPPOX Foundation
  • IQVIA Stem Cell Center
  • Janelia Research Campus
  • Janssen
  • Kalon Biotherapeutics
  • Kaneka Eurogentec
  • Kelley School of Business, Indiana University
  • King's College London, Guy's and St Thomas' NHS Foundation Trust
  • Kite Pharma
  • Kobe Biomedical Innovation Cluster
  • Kolon Life Sciences
  • Laboratory of Malaria Immunology and Vaccinology
  • Lentigen Technology
  • Lentiviral Lab, USC School of Pharmacy
  • Leuven Viral Vector Core
  • Lonza
  • Luminous BioSciences
  • Lund University
  • Lysogene
  • Massachusetts Eye and Ear
  • Massachusetts Life Science Center
  • MassBiologics
  • MaxCyte
  • Medigene
  • MeiraGTx
  • Merck
  • Merck Serono
  • Merial
  • Michael J. Fox Foundation for Parkinson Research
  • Mila's Miracle Foundation
  • MilliporeSigma
  • Ministry of Economy and Competitiveness
  • Mitsubishi
  • Molecular Diagnostic Services
  • Molecular Virology Core, Oregon National Primate Research Center, Oregon Health & Science University
  • MolMed
  • Myeloma Crowd Research Initiative
  • NanoCor Therapeutics
  • Nantes Gene Therapy Institute
  • National Cancer Institute
  • National Center for Advancing Translational Sciences
  • National Human Genome Research Institute
  • National Institute of Neurodegenerative Disorders and Stroke Center Core, University of Minnesota
  • National Institutes of Health
  • National Virus Vector Laboratory, University of Eastern Finland
  • Nature Technology
  • Naval Medical Research Center
  • Neuroscience CenterVector Core, Massachusetts General Hospital
  • Neuroscience Gene Vector and Virus Core, Stanford Medicine
  • NewLink Genetics
  • Nikon CeLL innovation
  • Novartis
  • Novasep
  • Ocular Gene Therapy Core, National Eye Institute
  • Okairos
  • Omnia Biologics
  • Orchard Therapeutics
  • Oxford BioMedica
  • Oxford Genetics
  • PacificGMP
  • Paragon Gene Therapy, Catalent Biologics
  • Penn Vector Core, University of Pennsylvania
  • Pfizer
  • PharmaChem Technologies
  • Pinchal & Company
  • PlasmidFactory
  • Powell Gene Therapy Center, University of Florida
  • Precigen
  • ProBioGen
  • ProMab Biotechnologies
  • Protein Sciences
  • Provecs Medical
  • Puresyn
  • Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia
  • Rayne Cell Therapy Suite, King's College London
  • REGENXBIO
  • Renova Therapeutics
  • Richter-Helm BioLogics
  • RIKEN BioResource Research Center
  • Roche
  • Rock Springs Capital
  • Rocket Pharmaceuticals
  • SAB-Technology
  • SAFC
  • Sanofi CEPiA
  • Sanofi Genzyme
  • Sanofi Pasteur
  • Sartorius Stedim Biotech
  • Scancell
  • Selecta Biosciences
  • Shanghai Sunway Biotech
  • Shenzhen SiBiono GeneTech
  • SignaGen Laboratories
  • SillaJen
  • Sino Biological
  • SIRION Biotech
  • Sofinnova Ventures
  • Spark Therapeutics
  • St Thomas' NHS Foundation Trust
  • Stevenage Bioscience Catalyst
  • Strathmann Biotec
  • Stratophase
  • Synpromics
  • Synthace
  • Synthetic Genomics
  • System Biosciences
  • T. Rowe Price Associates
  • Tecrea
  • Terry Fox Laboratory
  • Texas A&M University
  • The Finnish Fair Foundation
  • The Goldyne Savad Institute of Gene Therapy, Hadassah Medical Organization
  • The Jarvis Lab
  • The Wellcome Trust
  • The Wellcome Trust / BRC Clinical Research Facility and Cell Therapy Unit (CTU), King
  • 's College London
  • TheraBiologics
  • THERAVECTYS
  • Therexsys
  • Thermo Fisher Scientific
  • TissueGene
  • Touchlight Genetics
  • Transgene
  • Treeway
  • Twist Bioscience
  • TxCell
  • UAB Vector Production Facility
  • uniQure
  • Unit Biotech & ATMP's, University Medical Center Groningen
  • UniTech Pharma
  • University of Florida
  • University of Iowa Research Foundation
  • University of Liège
  • University of Massachusetts Medical School System
  • University of Oxford Clinical BioManufacturing Facility
  • University of Virginia School of Medicine
  • Vaccibody
  • Vaccine and Gene Therapy Institute
  • Valneva
  • VBI Vaccine
  • Vectalys
  • Vector Biolabs
  • Vector Core / GMP Facility, UC Davis Health
  • Vector Core Laboratory, Powell Gene Therapy Center, University of Florida
  • Vector Core of Gene Therapy, Laboratory of Nantes
  • Vector Core, Harvard Gene Therapy Initiative
  • Vector Core, Telethon Institute of Genetics and Medicine
  • Vector Core, University of Michigan Medical School
  • Vector Core, University of North Carolina
  • Vector Development and Production Facility, Roswell Park Comprehensive Cancer Center
  • Vector Development Core Laboratory, UC San Diego School of Medicine
  • Vector Production Facility, Indiana University
  • Vecura GMP Laboratory, Karolinska Institutet
  • VGXI
  • Vibalogics
  • Vical
  • Vigene Biosciences
  • Viral Core Facility, NeuroCure
  • Viral Core, Seattle Children's Research Institute
  • Viral Gene Transfer Core, Massachusetts Institute of Technology
  • Viral Vector and Cloning Core, University of Minnesota
  • Viral Vector Core / Clinical Manufacturing Facility, Nationwide Children's Hospital
  • Viral Vector Core Facility, University of Iowa Carver College of Medicine
  • Viral Vector Core Laboratory, National Institute of Environmental Health Sciences
  • Viral Vector Core Laboratory, The University of Tennessee Health Science Center
  • Viral Vector Core, Duke University
  • Viral Vector Core, Emory University School of Medicine
  • Viral Vector Core, Maine Medical Research Institute
  • Viral Vector Core, Sanford Burnham Prebys Medical Discovery Institute
  • Viral Vector Core, The Jackson Laboratory
  • Viral Vector Core, The Jenner Institute
  • Viral Vector Core, University of Massachusetts Medical School
  • Viral Vector Core, University of South Carolina School of Medicine
  • Viral Vector Facility, Neuroscience Center Zurich
  • Viral Vector Production Laboratory, Mayo Clinic Cancer Center
  • Viral Vector Production Unit, Universitat Autònoma de Barcelona-Vall d'Hebrón Institut de Recerca
  • Viral Vectors Laboratory, Louisiana State University School of Veterinary Medicine
  • ViralGEN
  • ViroMed
  • Virovek
  • VirusTech Core Facility, Karolinska Institutet
  • Vivante GMP Solutions
  • VIVEbiotech
  • Voyager Therapeutics
  • Waisman Biomanufacturing
  • Weber Laboratory, Icahn School of Medicine at Mount Sinai
  • Wellington Management
  • West Biotherapy (also known as EFS Atlantic Bio GMP)
  • Wolfson Gene Therapy Unit, University College of London
  • WuXi AppTec
  • Xpress Biologics
  • Yposkesi
  • Ziopharm Oncology

Segmentation

Close to USD 2 billion (by 2030) financial opportunity within the vector manufacturing market has been analyzed across the following segments:

  • Type of Vector
  • AAV
  • Adenoviral
  • Lentiviral
  • Retroviral
  • Plasmid DNA
  • Other Vectors
  • Application
  • Gene Therapy
  • T-Cell Therapy
  • Vaccines
  • Therapeutic Area
  • Oncological Disorders
  • Inflammation & Immunological Disorders
  • Neurological Disorders
  • Ophthalmological Disorders
  • Muscle Disorders
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Others
  • Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World